search
Back to results

Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis (WobeSmart)

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Wobenzym®
Placebo
Sponsored by
Mucos Pharma GmbH & Co. KG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

40 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female ≥ 40 years of age and with BMI ≤ 35 kg/m2;
  2. Uni- or bilateral femorotibial knee OA :

    1. Responding to clinical and radiological criteria of American College of Rheumatology (ACR);
    2. Symptomatic for more than 6 months in the index knee;
    3. Radiological Kellgren & Lawrence (K&L) grade II-III in standing x-rays from less than 12 months.
  3. Mild-to-Moderate mean knee pain score at rest or at walking over the last 24 hours on the index knee evaluated on VAS (0-100) ≥ 40 at baseline;
  4. Able to follow the instructions of the study;
  5. Having signed an informed consent.

Exclusion Criteria:

Related to knee:

  1. Recent macro-trauma of the knee responsible of the symptomatic knee left to the Investigator's discretion;
  2. Concurrent articular disease interfering with the evaluation of pain left to the Investigator's discretion;
  3. Prosthesis in the target knee;
  4. Knee swelling requiring corticosteroids local injection.

    Related to treatments:

  5. Analgesics to manage knee pain 24 hours before inclusion visit;
  6. Corticosteroids injection in the target knee in the last 3 months;
  7. Hyaluronan injection in the target knee in the last 6 months;
  8. Arthroscopy in the last 6 months;
  9. Oral corticotherapy ≥ 5mg/day (in Prednisolone equivalent) in the last 3 months;
  10. Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) or dietary supplement, i.e., curcuma extract, chondroitin, glucosamine, diacerein or avocado-soya unsaponifiables in the last 3 months;
  11. An anticipated need for any forbidden treatments during the trial;
  12. Contraindications to the product :

    1. severe hepatic and renal impairment
    2. congenital or acquired coagulation disorders, e.g. haemophilia
    3. severe liver and/or kidney damage
    4. hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  13. Hypersensitivity or allergy to the product components, and pineapple;
  14. Treatments based on strontium ranelate, bisphosphonates, selective estrogen-receptor modulator (SERM) and parathormone (PTH) in the last 12 months;
  15. Treatment based on zoledronate in the last 2 years;
  16. Treatment based on denosumab in the last 6 months;
  17. Treatment with anticoagulants and/or anti-platelet agents

    Related to associated diseases:

  18. Any severe, uncontrolled and limiting disease left to the Investigator's discretion;
  19. Patient with widespread pain/depression (e.g. fibromyalgia);
  20. Lower or upper extremity surgery or fracture in the last 6 months;
  21. Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee;
  22. Severe alteration of mobility enabling functional evaluation.

    Related to subjects

  23. Close collaborators to the investigational team, the study coordinator (ARTIALIS) or to the Sponsor;
  24. Currently participating or having participated in another therapeutic clinical trial in the three previous months;
  25. Having made a blood donation in the past month;
  26. Under guardianship or judicial protection;
  27. Pregnancy, breastfeeding, planned conception, or premenopausal women without effective contraception (tablet, patch, ring, diaphragm, implant and intrauterine device, tubal ligation or hysterectomy);
  28. Counter-indication to an MRI examination.

Sites / Locations

  • Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim
  • Centre Hospitalier Universitaire (CHU) Brugmann
  • Cliniques Universitaires Saint Luc UCL
  • UZ Brussel
  • Centre Hospitalier Régional de la Citadelle

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Wobenzym®

PLACEBO

Arm Description

Medicinal product Wobenzym® containing Bromelain (67.5-76.5 mg) adjusted to 450 FIP units, Trypsin (32-48mg) adjusted to 24 µkat and Rutoside trihydrate (100mg).

No active ingredients. The active ingredients will be substituted by microcrystalline cellulose.

Outcomes

Primary Outcome Measures

Effects on cartilage biomarkers
Change in sera biomarkers sColl2-1, sColl2-1NO2, sCOMP, sPIIANP and urine biomarker uCTXII between visit 0 and visit 5 measured using immunoassays (Enzyme-linked Immunosorbent assay, ELISA)
Effects on markers of innate immune response
Change in the expression of M1/M2 Polarization specific membrane markers on fresh blood macrophage, between visit 0 and visit 5 using flow cytometry
Effects on systemic inflammatory markers
Change in sera biomarkers NLRP 3 Inflammasome, α-2-macroglobulin, IL-1β, TNFα, IL-6, IL-10, IL-4 between visit 0 and visit 5 measured using immunoassays (Enzyme-linked Immunosorbent assay, ELISA)
Effects on cellular pathways
Change in plasma proteomic profile using liquid chromatography-tandem mass spectrometry (LC-MS/MS) between visit 0 and visit 5.

Secondary Outcome Measures

Vital signs and anthropomorphic measurements
Changes in systolic and diastolic Blood pressure (BP) in mmHg between visit -1 and visit 6
Vital signs and anthropomorphic measurements
Changes in Heart Rate (HR) measured in beats per minute between visit -1 and visit 6
Vital signs and anthropomorphic measurements
Changes in Temperature measured in degrees Celsius between visit -1 and visit 6
Vital signs and anthropomorphic measurements
Changes in weight measured in kilograms, height measured in centimeters and BMI (weight and height will be combined to calculate BMI in kg/m2 between visit -1 and visit 6
Knee Pain
Changes in knee pain at rest and while walking using a Visual Analogue Scale (1 to 100 mm scale where a higher score indicates greater pain intensity) between visit 0 and visit 6
Knee Function
Changes in knee function using Knee injury and Osteoarthristis Outcome Score (KOOS). KOOS is a self-administrated questionnaire comprising 5 subscales: pains, symptoms, activities of daily living, sports and recreation function, and quality of life (0 to 100 scale where 100 indicates the best result) between visit 0 and visit 6
Patient global assessment of disease activity (PGADA)
Changes in PGADA using a Visual Analogue Scale (1 to 100 mm scale where a higher score indicates a higher level of disease activity /a worse global health) between visit 0 and visit 6
Patient physical activity
Effects on subject mobility using a connected device to record heart rate (beats/min between visit 0 and visit 6
Patient physical activity
Effects on subject mobility using a connected device to record number of steps/day taken between visit 0 and visit 6
Patient physical activity
Effects on subject mobility using a connected device to record number of climbed stairs/day between visit 0 and visit 6
Patient physical activity
Effects on subject mobility using a connected device to record intensive exercise minutes/day between visit 0 and visit 6
Patient physical activity
Effects on subject mobility using a connected device to record calories burned/day between visit 0 and visit 6minutes/day between visit 0 and visit 6
Body metabolism
Effects on body metabolism marker TGF-β1, TGF β 2, TGF-β 3 using immunoassays (Enzyme-linked Immunosorbent assay, ELISA) between visit 0 and visit 5
Clinical chemistry
Number of participants with changes in clinical chemistry measurements (concentration of myostatin, hemoglobin, hematocrit, erythrocyte count, TG, TC, LDL, HDL, glucose, hsCRP, uric acid, coagulation markers and key hepatic enzymes) using immunoassays between visit 0 and visit 5
Joint structure modification
Effects on joint structure using either MRI Osteoarthritis Knee Score (MOAKS - a semi quantitative scoring tool. Fourteen subregions are defined for scoring of articular cartilage and bone marrow lesions from grade 0 to grade 3. The more the grade increases, the more important the pathology) or Whole-Organ Magnetic Resonance Imaging Score (WORMS - a semi quantitative scoring tool that examines a spectrum of OA-related structural abnormalities including soft tissue, cartilage and bone in the knee at various anatomical subregion locations. The more the score increases, the more important the pathology) between visit 0 and visit 6
Volume of joint effusion
Volume of joint effusion by MRI using volumetric segmentation method between visit 0 and visit 6
Tolerance
Number of patients with Adverse Events, type of reported adverse events and subject drop out between visit -1 and visit 6
Compliance
Tablet count of investigational product between visit 0 and visit 6
Responder rate to treatment
Responder rate to treatment defined as changes in knee pain and/or knee function and/or patients disease activity using Pain and/or PGADA and/or KOOS according to recommendations of OMERACT OARSI (Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology (OMERACT), defined by either a high improvement in pain or in function >50% and absolute change >20 or an improvement in at least 2 of the 3 following: pain >20% and absolute change >10, function >20% and absolute change >10, patient's global assessment >20% and absolute change >10 (between visit 0 and visit 6

Full Information

First Posted
May 25, 2021
Last Updated
October 11, 2022
Sponsor
Mucos Pharma GmbH & Co. KG
Collaborators
Société des Produits Nestlé (SPN), Artialis
search

1. Study Identification

Unique Protocol Identification Number
NCT05038410
Brief Title
Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis
Acronym
WobeSmart
Official Title
Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
April 30, 2021 (Actual)
Primary Completion Date
October 5, 2022 (Actual)
Study Completion Date
October 5, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mucos Pharma GmbH & Co. KG
Collaborators
Société des Produits Nestlé (SPN), Artialis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the pharmacodynamic profile of an oral enzyme treatment with Bromelain, Trypsin and Rutoside in subjects with osteoarthritis.
Detailed Description
This study is a randomised, placebo controlled, two parallel arms, cross over, and multicentric trial in 40 male and female subjects suffering from osteoarthritis. While is it well established that Wobenzyme is safe and have proven efficacy in painful conditions, inflammation and osteoarthritis, little is known about its clear mechanism of action underlying its clinical efficacy. This study hypothesises that oral enzyme combination therapy with Wobenzyme will lead to systemic pharmacodynamic effects which will be documented by a holistic assessment of the inflammasome, innate immune system, cartilage turnover, systemic inflammatory markers, as well as potential cellular pathways.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Wobenzym®
Arm Type
Active Comparator
Arm Description
Medicinal product Wobenzym® containing Bromelain (67.5-76.5 mg) adjusted to 450 FIP units, Trypsin (32-48mg) adjusted to 24 µkat and Rutoside trihydrate (100mg).
Arm Title
PLACEBO
Arm Type
Placebo Comparator
Arm Description
No active ingredients. The active ingredients will be substituted by microcrystalline cellulose.
Intervention Type
Drug
Intervention Name(s)
Wobenzym®
Intervention Description
Wobenzym®
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Microcrystalline cellulose
Primary Outcome Measure Information:
Title
Effects on cartilage biomarkers
Description
Change in sera biomarkers sColl2-1, sColl2-1NO2, sCOMP, sPIIANP and urine biomarker uCTXII between visit 0 and visit 5 measured using immunoassays (Enzyme-linked Immunosorbent assay, ELISA)
Time Frame
20 weeks
Title
Effects on markers of innate immune response
Description
Change in the expression of M1/M2 Polarization specific membrane markers on fresh blood macrophage, between visit 0 and visit 5 using flow cytometry
Time Frame
20 weeks
Title
Effects on systemic inflammatory markers
Description
Change in sera biomarkers NLRP 3 Inflammasome, α-2-macroglobulin, IL-1β, TNFα, IL-6, IL-10, IL-4 between visit 0 and visit 5 measured using immunoassays (Enzyme-linked Immunosorbent assay, ELISA)
Time Frame
20 weeks
Title
Effects on cellular pathways
Description
Change in plasma proteomic profile using liquid chromatography-tandem mass spectrometry (LC-MS/MS) between visit 0 and visit 5.
Time Frame
20 weeks
Secondary Outcome Measure Information:
Title
Vital signs and anthropomorphic measurements
Description
Changes in systolic and diastolic Blood pressure (BP) in mmHg between visit -1 and visit 6
Time Frame
40 weeks
Title
Vital signs and anthropomorphic measurements
Description
Changes in Heart Rate (HR) measured in beats per minute between visit -1 and visit 6
Time Frame
40 weeks
Title
Vital signs and anthropomorphic measurements
Description
Changes in Temperature measured in degrees Celsius between visit -1 and visit 6
Time Frame
40 weeks
Title
Vital signs and anthropomorphic measurements
Description
Changes in weight measured in kilograms, height measured in centimeters and BMI (weight and height will be combined to calculate BMI in kg/m2 between visit -1 and visit 6
Time Frame
40 weeks
Title
Knee Pain
Description
Changes in knee pain at rest and while walking using a Visual Analogue Scale (1 to 100 mm scale where a higher score indicates greater pain intensity) between visit 0 and visit 6
Time Frame
36 weeks
Title
Knee Function
Description
Changes in knee function using Knee injury and Osteoarthristis Outcome Score (KOOS). KOOS is a self-administrated questionnaire comprising 5 subscales: pains, symptoms, activities of daily living, sports and recreation function, and quality of life (0 to 100 scale where 100 indicates the best result) between visit 0 and visit 6
Time Frame
36 weeks
Title
Patient global assessment of disease activity (PGADA)
Description
Changes in PGADA using a Visual Analogue Scale (1 to 100 mm scale where a higher score indicates a higher level of disease activity /a worse global health) between visit 0 and visit 6
Time Frame
36 weeks
Title
Patient physical activity
Description
Effects on subject mobility using a connected device to record heart rate (beats/min between visit 0 and visit 6
Time Frame
36 weeks
Title
Patient physical activity
Description
Effects on subject mobility using a connected device to record number of steps/day taken between visit 0 and visit 6
Time Frame
36 weeks
Title
Patient physical activity
Description
Effects on subject mobility using a connected device to record number of climbed stairs/day between visit 0 and visit 6
Time Frame
36 weeks
Title
Patient physical activity
Description
Effects on subject mobility using a connected device to record intensive exercise minutes/day between visit 0 and visit 6
Time Frame
36 weeks
Title
Patient physical activity
Description
Effects on subject mobility using a connected device to record calories burned/day between visit 0 and visit 6minutes/day between visit 0 and visit 6
Time Frame
36 weeks
Title
Body metabolism
Description
Effects on body metabolism marker TGF-β1, TGF β 2, TGF-β 3 using immunoassays (Enzyme-linked Immunosorbent assay, ELISA) between visit 0 and visit 5
Time Frame
20 weeks
Title
Clinical chemistry
Description
Number of participants with changes in clinical chemistry measurements (concentration of myostatin, hemoglobin, hematocrit, erythrocyte count, TG, TC, LDL, HDL, glucose, hsCRP, uric acid, coagulation markers and key hepatic enzymes) using immunoassays between visit 0 and visit 5
Time Frame
20 weeks
Title
Joint structure modification
Description
Effects on joint structure using either MRI Osteoarthritis Knee Score (MOAKS - a semi quantitative scoring tool. Fourteen subregions are defined for scoring of articular cartilage and bone marrow lesions from grade 0 to grade 3. The more the grade increases, the more important the pathology) or Whole-Organ Magnetic Resonance Imaging Score (WORMS - a semi quantitative scoring tool that examines a spectrum of OA-related structural abnormalities including soft tissue, cartilage and bone in the knee at various anatomical subregion locations. The more the score increases, the more important the pathology) between visit 0 and visit 6
Time Frame
36 weeks
Title
Volume of joint effusion
Description
Volume of joint effusion by MRI using volumetric segmentation method between visit 0 and visit 6
Time Frame
36 weeks
Title
Tolerance
Description
Number of patients with Adverse Events, type of reported adverse events and subject drop out between visit -1 and visit 6
Time Frame
40 weeks
Title
Compliance
Description
Tablet count of investigational product between visit 0 and visit 6
Time Frame
36 weeks
Title
Responder rate to treatment
Description
Responder rate to treatment defined as changes in knee pain and/or knee function and/or patients disease activity using Pain and/or PGADA and/or KOOS according to recommendations of OMERACT OARSI (Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology (OMERACT), defined by either a high improvement in pain or in function >50% and absolute change >20 or an improvement in at least 2 of the 3 following: pain >20% and absolute change >10, function >20% and absolute change >10, patient's global assessment >20% and absolute change >10 (between visit 0 and visit 6
Time Frame
36 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female ≥ 40 years of age and with BMI ≤ 35 kg/m2; Uni- or bilateral femorotibial knee OA : Responding to clinical and radiological criteria of American College of Rheumatology (ACR); Symptomatic for more than 6 months in the index knee; Radiological Kellgren & Lawrence (K&L) grade II-III in standing x-rays from less than 12 months. Mild-to-Moderate mean knee pain score at rest or at walking over the last 24 hours on the index knee evaluated on VAS (0-100) ≥ 40 at baseline; Able to follow the instructions of the study; Having signed an informed consent. Exclusion Criteria: Related to knee: Recent macro-trauma of the knee responsible of the symptomatic knee left to the Investigator's discretion; Concurrent articular disease interfering with the evaluation of pain left to the Investigator's discretion; Prosthesis in the target knee; Knee swelling requiring corticosteroids local injection. Related to treatments: Analgesics to manage knee pain 24 hours before inclusion visit; Corticosteroids injection in the target knee in the last 3 months; Hyaluronan injection in the target knee in the last 6 months; Arthroscopy in the last 6 months; Oral corticotherapy ≥ 5mg/day (in Prednisolone equivalent) in the last 3 months; Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) or dietary supplement, i.e., curcuma extract, chondroitin, glucosamine, diacerein or avocado-soya unsaponifiables in the last 3 months; An anticipated need for any forbidden treatments during the trial; Contraindications to the product : severe hepatic and renal impairment congenital or acquired coagulation disorders, e.g. haemophilia severe liver and/or kidney damage hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption Hypersensitivity or allergy to the product components, and pineapple; Treatments based on strontium ranelate, bisphosphonates, selective estrogen-receptor modulator (SERM) and parathormone (PTH) in the last 12 months; Treatment based on zoledronate in the last 2 years; Treatment based on denosumab in the last 6 months; Treatment with anticoagulants and/or anti-platelet agents Related to associated diseases: Any severe, uncontrolled and limiting disease left to the Investigator's discretion; Patient with widespread pain/depression (e.g. fibromyalgia); Lower or upper extremity surgery or fracture in the last 6 months; Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee; Severe alteration of mobility enabling functional evaluation. Related to subjects Close collaborators to the investigational team, the study coordinator (ARTIALIS) or to the Sponsor; Currently participating or having participated in another therapeutic clinical trial in the three previous months; Having made a blood donation in the past month; Under guardianship or judicial protection; Pregnancy, breastfeeding, planned conception, or premenopausal women without effective contraception (tablet, patch, ring, diaphragm, implant and intrauterine device, tubal ligation or hysterectomy); Counter-indication to an MRI examination.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valerie Badot
Organizational Affiliation
Centre Hospitalier Universitaire (CHU) Brugmann
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Didier Urbin-Choffray
Organizational Affiliation
Centre Hospitalier Regional de la Citadelle
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Karl Brabants
Organizational Affiliation
Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jean-Emile Dubuc
Organizational Affiliation
Cliniques Universitaires Saint Luc UCL
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Siddhartha Lieten
Organizational Affiliation
Universitair Ziekenhuis Brussel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim
City
Antwerpen
ZIP/Postal Code
2020
Country
Belgium
Facility Name
Centre Hospitalier Universitaire (CHU) Brugmann
City
Bruxelles
ZIP/Postal Code
1020
Country
Belgium
Facility Name
Cliniques Universitaires Saint Luc UCL
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
UZ Brussel
City
Jette
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Centre Hospitalier Régional de la Citadelle
City
Liège
ZIP/Postal Code
4000
Country
Belgium

12. IPD Sharing Statement

Learn more about this trial

Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis

We'll reach out to this number within 24 hrs